
    
      PROTOCOL OUTLINE: Participants are treated with subcutaneous leuprolide acetate followed by
      oral spironolactone. Each treatment is administered daily for 6 weeks, with a 6-week washout
      between drugs.

      Patients and controls are alternately assigned to begin treatment with leuprolide acetate or
      spironolactone.
    
  